84 related articles for article (PubMed ID: 22364953)
1. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
2. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
3. QSAR models for P450 (2D6) substrate activity.
Ringsted T; Nikolov N; Jensen GE; Wedebye EB; Niemelä J
SAR QSAR Environ Res; 2009; 20(3-4):309-25. PubMed ID: 19544194
[TBL] [Abstract][Full Text] [Related]
4. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
[TBL] [Abstract][Full Text] [Related]
5. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
Peng CC; Rushmore T; Crouch GJ; Jones JP
Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
Yale SH; Glurich I
J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
[TBL] [Abstract][Full Text] [Related]
7. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
8. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
Ahlström MM; Ridderström M; Zamora I
J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
[TBL] [Abstract][Full Text] [Related]
10. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.
Mannheimer B; von Bahr C; Pettersson H; Eliasson E
Ther Drug Monit; 2008 Oct; 30(5):565-9. PubMed ID: 18728628
[TBL] [Abstract][Full Text] [Related]
11. Structure-based CoMFA as a predictive model - CYP2C9 inhibitors as a test case.
Yasuo K; Yamaotsu N; Gouda H; Tsujishita H; Hirono S
J Chem Inf Model; 2009 Apr; 49(4):853-64. PubMed ID: 19391630
[TBL] [Abstract][Full Text] [Related]
12. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.
McMasters DR; Torres RA; Crathern SJ; Dooney DL; Nachbar RB; Sheridan RP; Korzekwa KR
J Med Chem; 2007 Jul; 50(14):3205-13. PubMed ID: 17559204
[TBL] [Abstract][Full Text] [Related]
14. Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.
Saraceno M; Massarelli I; Imbriani M; James TL; Bianucci AM
Chem Biol Drug Des; 2011 Aug; 78(2):236-51. PubMed ID: 21575140
[TBL] [Abstract][Full Text] [Related]
15. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
16. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
17. Understanding CYP2D6 interactions.
de Groot MJ; Wakenhut F; Whitlock G; Hyland R
Drug Discov Today; 2009 Oct; 14(19-20):964-72. PubMed ID: 19638317
[TBL] [Abstract][Full Text] [Related]
18. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
Rettie AE; Jones JP
Annu Rev Pharmacol Toxicol; 2005; 45():477-94. PubMed ID: 15822186
[TBL] [Abstract][Full Text] [Related]
19. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Afzelius L; Zamora I; Masimirembwa CM; Karlén A; Andersson TB; Mecucci S; Baroni M; Cruciani G
J Med Chem; 2004 Feb; 47(4):907-14. PubMed ID: 14761192
[TBL] [Abstract][Full Text] [Related]
20. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
Locuson CW; Rock DA; Jones JP
Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
